Crinetics Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGCrinetics Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 48), showing significant lag compared to the market leaders. Earnings contraction of 18% provides fundamental context to the price action. However, price is extended 121% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $38.63 | +116.26% | ABOVE |
| 50 SMA | $37.74 | +121.30% | ABOVE |
| 100 SMA | $38.49 | +117.01% | ABOVE |
| 150 SMA | $42.20 | +97.91% | ABOVE |
| 200 SMA | $42.13 | +98.27% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CRNX in an uptrend right now?
CRNX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CRNX overbought or oversold?
CRNX's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CRNX outperforming the market?
CRNX has a Relative Strength (RS) Rating of 48 out of 99. CRNX is currently lagging the broader market.
Where is CRNX in its 52-week range?
CRNX is trading at $83.53, which is 100% of its 52-week high ($83.63) and 100% above its 52-week low ($25.83).
How volatile is CRNX?
CRNX has a Beta of 1.03 and 52-week volatility of 58%. It's more volatile than the S&P 500 - expect bigger swings.